# Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

Source: https://onco.cc/trials/nct07567014/  
OnCo record `nct07567014` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Emapalumab in Multiple myeloma, run by NYU Langone Health, not yet recruiting.

## Summary

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS is a phase 2 interventional study registered as NCT07567014 by NYU Langone Health, with 60 participants planned, started 2026-05-11 and due to reach its primary completion in 2028-05-31. Interventions recorded: Emapalumab. Conditions recorded: Multiple Myeloma, Large B-cell Lymphoma (LBCL).

Linked to the drug Emapalumab because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07567014
- Phase: 2
- Setting: A Phase II Study of the Interferon Gamma Inhibitor Emapalumab for Prophylaxis of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Lymphoma and Multiple Myeloma Receiving Bispecific T-Cell Engagers
- Sponsor: NYU Langone Health
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07567014: https://clinicaltrials.gov/study/NCT07567014

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Emapalumab](https://onco.cc/drugs/emapalumab/)

---
JSON: https://onco.cc/api/v1/entities/nct07567014.json